Evidence map›Paper›PMID 30844328›Full record

ArticleJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research2019

Hepatic IFN-Induced Protein with Tetratricopeptide Repeats Regulation of HCV Infection.

Yuji Ishida, Masakazu Kakuni, Bo-Ram Bang, Go Sugahara, Daryl T-Y Lau, Chise Tateno-Mukaidani, Meng Li, Michael Gale, Takeshi Saito

Erratum issuedAbstract read
In one paragraph

Article in Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yuji Ishida1 Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Masakazu Kakuni2 PhoenixBio, Kagamiyama, Higashi-Hiroshima City, Hiroshima, Japan.
Bo-Ram Bang1 Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Go Sugahara1 Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Daryl T-Y Lau3 Department of Medicine, Liver Center, Beth Israel Deaconess, Harvard Medical School, Boston, Massachusetts.
Chise Tateno-Mukaidani2 PhoenixBio, Kagamiyama, Higashi-Hiroshima City, Hiroshima, Japan.
Meng Li4 Bioinformatics Service, Norris Medical Library, University of Southern California, Los Angeles, California.
Michael Gale5 Department of Immunology, University of Washington School of Medicine, Seattle, Washington.
Takeshi Saito1 Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
University of Southern California · USUniversity of Washington · US

Funding

USC RESEARCH CENTER FOR LIVER DISEASES: PILOT PROGRAMSP30DK048522 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAPLOWITZ, NEIL · 1995 to 2020
$21.8M
Mechanisms of hepatic innate immune activation by HCVR01AI127463 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL, ROSEN, HUGO RAMON · 2017 to 2021
$2.8M
The Host Response to Hepatitis C VirusR01AI118916 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL · 2016 to 2020
$2.5M
Innate Defense Program against HCVR01DK101773 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SAITO, TAKESHI · 2015 to 2019
$1.9M
Impact of Occult Hepatitis C Virus Infection in Progression of Liver DiseasesR21AI139954 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SAITO, TAKESHI · 2018 to 2019
$454k
Retinoid regulation of hepatic innate immunity.R21AA022751 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SAITO, TAKESHI · 2014 to 2015
$427k
NIAAA NIH HHS R21 AA022751NIAID NIH HHS R01 AI118916NIAID NIH HHS R01 AI127463NIAID NIH HHS R21 AI139954NIDDK NIH HHS P30 DK048522NIDDK NIH HHS R01 DK101773
6 · The paper itself

Abstract

Interferons (IFNs) suppress viral infection through the induction of >400 interferon-stimulated genes (ISGs). Among ISGs, IFN-induced protein with tetratricopeptide repeats (IFITs) is one of the most potent and well-characterized ISGs. IFIT family consists of 4 cluster genes. It has been suggested that the antiviral action of each IFIT employs distinct mechanisms. In addition, it has been shown that each IFIT exhibits its antiviral properties partially in a pathogen-specific manner. To date, the expression profile of IFITs in the liver, as well as the antiviral potency of the individual IFITs in the regulation of hepatitis C virus (HCV) infection, is not yet fully defined. Our previous study found that the expression of hepatic IFITs is well correlated with the outcome of IFN-based antiviral therapy. This study explored the significance of each IFIT in the suppression of HCV. Our in vitro and in vivo studies with humanized liver chimeric mouse system revealed that IFIT1, 2, and 3/4 play an important role in the suppression of HCV. In addition, our in vitro experiment found that all IFITs possess a comparable anti-HCV potency. Follow-up studies collectively indicated that IFITs suppress HCV likely through 2 distinct mechanisms: (1) inhibition of internal ribosome entry site-dependent viral protein translation initiation complex according to experiments with bicistronic reporter assay as well as confocal microscopic analyses and (2) sequestration of viral genome based on an experiment using replication defective viral genome. In conclusion, our study defined the importance of IFITs in the regulation of HCV and also suggested the multifaceted antiviral actions.

Indexed as

Antiviral AgentsCell LineHepacivirusHepatitis CHumansInterferonsTetratricopeptide RepeatVirus ReplicationAntiviral AgentsInterferonshepatitis C virushumanized liver chimeric miceIFN-induced protein with tetratricopeptide repeatsinterferon stimulated genes

Identifiers

PMID30844328
PMCPMC6441290
OpenAlexW2920794833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.